drugset / Trial / NCT03281096

A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

NCT03281096

Phase 2/3 Completed 1000 enrolled Xijing Hospital of Digestive Diseases
RandomizedParallel-groupTriple-blindPrevention

Summary

Experimental studies in animals and observational studies in humans suggest that fusobacterium nucleatum is associates with stages of colorectal neoplasia development, and Berberine Hydrochloride could rescue Fusobacterium nucleatum-induced colorectal tumorigenesis by modulating the tumor microenvironment. Whether regular Berberine Hydrochloride use may decrease the risk of colorectal adenomas, the precursors to most colorectal cancers is worth to further study.

Timeline

Start
2017-08-29
Primary completion
2020-10-12
Completion
2021-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Berberine Traditional medicine (herbal / TCM) 300 mg Oral

Indications